-+ 0.00%
-+ 0.00%
-+ 0.00%
Knight Therapeutics wins Colombia approval for Tavalisse in chronic ITP
Share
Listen to the news
Knight Therapeutics wins Colombia approval for Tavalisse in chronic ITP
  • Knight Therapeutics won INVIMA clearance in Colombia for Tavalisse to treat adults with chronic immune thrombocytopenia.
  • Label targets patients with inadequate response, loss of response, or intolerance to corticosteroids and intravenous immunoglobulin.
  • Company expects a Colombia launch in H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609011800PRIMZONEFULLFEED9819730) on September 01, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending